Table 1. Clinicopathological features of IBC subjects according to TCGA database.
| Characteristic | Low-CIAPIN1 expression | High-CIAPIN1 expression | P |
|---|---|---|---|
| Total number of patients | 532 | 533 | |
| T stage, n (%) | |||
| T1 | 155 (14.6) | 120 (11.3) | <0.001 |
| T2 | 278 (26.2) | 337 (31.7) | |
| T3 | 83 (7.8) | 54 (5.1) | |
| T4 | 15 (1.4) | 20 (1.9) | |
| N stage, n (%) | |||
| N0 | 266 (25.4) | 241 (22.6) | 0.075 |
| N1 | 170 (16.3) | 179 (17.1) | |
| N2 | 46 (4.4) | 70 (6.7) | |
| N3 | 40 (3.8) | 34 (3.3) | |
| M stage, n (%) | |||
| M0 | 437 (48.1) | 452 (49.7) | 0.142 |
| M1 | 6 (0.7) | 14 (1.5) | |
| Pathologic stage, n (%) | |||
| Stage I | 102 (9.8) | 78 (7.5) | 0.126 |
| Stage II | 299 (28.7) | 307 (29.5) | |
| Stage III | 114 (10.9) | 124 (11.9) | |
| Stage IV | 6 (0.6) | 12 (1.2) | |
| Race, n (%) | |||
| Asian | 21 (2.2) | 39 (3.7) | 0.001 |
| Black or African American | 74 (7.6) | 105 (10.8) | |
| White | 391 (40.1) | 346 (35.5) | |
| Age (years), n (%) | |||
| ≤60 | 265 (24.9) | 323 (30.3) | <0.001 |
| >60 | 267 (25.1) | 210 (19.7) | |
| Histological type, n (%) | |||
| Infiltrating ductal carcinoma | 314 (32.7) | 443 (46.2) | <0.001 |
| Infiltrating lobular carcinoma | 169 (17.6) | 33 (3.4) | |
| ER status, n (%) | |||
| Negative | 68 (6.7) | 169 (16.6) | <0.001 |
| Indeterminate | 0 (0) | 2 (0.2) | |
| Positive | 444 (43.7) | 334 (32.8) | |
| PR status, n (%) | |||
| Negative | 120 (11.8) | 218 (21.5) | <0.001 |
| Indeterminate | 1 (0.1) | 3 (0.3) | |
| Positive | 391 (38.5) | 283 (27.9) | |
| HER2 status, n (%) | |||
| Negative | 280 (39.1) | 268 (37.4) | 0.056 |
| Indeterminate | 3 (0.4) | 9 (1.3) | |
| Positive | 68 (9.5) | 89 (12.4) | |
| PAM50, n (%) | |||
| Normal | 19 (1.8) | 21 (2.0) | <0.001 |
| LumA | 357 (33.5) | 194 (18.2) | |
| LumB | 83 (7.8) | 119 (11.2) | |
| Her2 | 28 (2.6) | 54 (5.1) | |
| Basal | 45 (4.2) | 145 (13.6) | |
| Menopause status, n (%) | |||
| Pre | 98 (10.3) | 126 (13.2) | 0.129 |
| Peri | 19 (1.8) | 20 (2.1) | |
| Post | 357 (37.3) | 336 (35.1) | |
| Radiation_therapy, n (%) | |||
| No | 222 (22.8) | 210 (21.6) | 0.715 |
| Yes | 270 (27.8) | 270 (27.8) | |
| OS event, n (%) | |||
| Alive | 466 (43.8) | 452 (42.4) | 0.218 |
| Dead | 66 (6.2) | 81 (7.6) | |
| DSS event, n (%) | |||
| Alive | 493 (47.1) | 472 (45.1) | 0.021 |
| Dead | 30 (2.9) | 51 (4.9) | |
| PFI event, n (%) | |||
| Alive | 472 (44.3) | 450 (42.3) | 0.049 |
| Dead | 60 (5.6) | 83 (7.8) | |
| Age, median [IQR] | 61 [51, 69] | 56 [47, 66] | <0.001 |
IBC, invasive breast cancer; TCGA, The Cancer Genome Atlas; CIAPIN1, Cytokine-induced apoptosis inhibitor 1; T, tumor; N, lymph node; M, metastasis; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; PAM50, prediction analysis of microarray 50; OS, overall survival; DSS, disease specific survival; PFI, progress free interval; IQR, interquartile range.